A
AbCellera Biologics D
D
ABCL
10.605
USD
-0.72
(-6.36%)
Post Trading·10.760USD+0.155(+1.46%)
Volume
432,516
EPS
-1
Div Yield
-
P/E
-20
Market Cap
3,436,522,285
Title: AbCellera Biologics
Sector: Healthcare
Industry: Biotechnology
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.